Ad
Search
Generic filters
Filter by content type
Taxonomy terms

VRNA – Verona Pharma PLC

🔒

Subscribe for full access

Unlock Industry-grade Shariah Compliance for US, UK, Canada, Germany, GCC, Europe and India. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.

We provide unparalleled value and service.

Get started from just $1/month

Ad

Recommendation Rating

1.43

1

2

3

4

5

1 = STRONG BUY | 2 = BUY | 3 = HOLD | 4 = UNDERPERFORM | 5 = SELL

Analysts’ Price Targets

Mean 24.71

Low: 17

High: 31

Total Analysts: 6

Company Profile

Verona Pharma Plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. It is developing inhaled ensifentrine for the treatment of chronic obstructive pulmonary disease (COPD). The Company is evaluating nebulized ensifentrine in its Phase III clinical program ENHANCE for COPD maintenance treatment. Its product candidate, ensifentrine, is an investigational, inhaled, dual inhibitor of the phosphodiesterase 3 and 4 (PDE3 and PDE4) enzymes, which is designed to act as both a bronchodilator and an anti-inflammatory agent. The Company’s two additional formulations of ensifentrine are in Phase II development for the treatment of COPD: dry powder inhaler (DPI) and pressurized metered-dose inhaler (pMDI). The Company’s wholly owned subsidiary is Verona Pharma, Inc.

We do our best to screen stocks as accurately as possible. Please let us know in the comments if you spot an error or find something questionable. Jazaak Allahu khairan

Ad

Responses